Bharat Biotech owned COVID-19 vaccine, Covaxin accrued Good Manufacturing Practice certification from the Hungarian administration, this Thursday. The compliance was granted from the National Institute of Pharmacy and Nutrition Hungary for the manufacture of Covaxin.
“Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatory. #BharatBiotech #COVAXIN #covaxininhungary,” added Bharat Biotech, through a tweet.
Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories.#BharatBiotech #COVAXIN #covaxininhungary pic.twitter.com/0x8BLF2jWR
— BharatBiotech (@BharatBiotech) August 5, 2021
With this approval, Bharat Biotech achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic, averred Bharat Biotech in an official statement.
The GMP certificate is now registered on the EudraGMDP portal, governed by the European Community of manufacturing clearance and certificates of good manufacturing practice.
Bharat Biotech also aims to confer documentation to issue an Emergency Use Authorization (EUA) in several other countries globally to augment their reach. “The recognition complements our commitment to driving world-class innovation and being a frontrunner in the research and development of vaccines,” said the company’s statement.
India’s Covaxin is one among the four vaccines approved by the drug regulator authority and is being successfully used in the inoculation drive over different states. The remaining three tested vaccines are Covishield by AstraZeneca, Sputnik V by Russia’s Gamaleya Institute and Moderna vaccine.